Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation

Background Dupilumab, a fully human monoclonal antibody that binds IL‐4Rα and inhibits signaling of both IL‐4 and IL‐13, has shown efficacy across multiple diseases with underlying type 2 signatures and is approved for treatment of asthma, atopic dermatitis, and chronic sinusitis with nasal polyposi...

Full description

Saved in:

Bibliographic Details
Published in:	Allergy (Copenhagen) Vol. 75; no. 5; pp. 1188 - 1204
Main Authors:	Le Floc’h, Audrey, Allinne, Jeanne, Nagashima, Kirsten, Scott, George, Birchard, Dylan, Asrat, Seblewongel, Bai, Yu, Lim, Wei Keat, Martin, Joel, Huang, Tammy, Potocky, Terra B., Kim, Jee H., Rafique, Ashique, Papadopoulos, Nicholas J., Stahl, Neil, Yancopoulos, George D., Murphy, Andrew J., Sleeman, Matthew A., Orengo, Jamie M.
Format:	Journal Article
Language:	English
Published:	Denmark Blackwell Publishing Ltd 01.05.2020 John Wiley and Sons Inc
Subjects:	Allergens Allergies Animals Antibodies, Monoclonal, Humanized Asthma Atopic dermatitis Cell culture Chemokines cytokines dupilumab IL‐13 IL‐4 Immunotherapy Infiltration Inflammation Interleukin-13 Interleukin-4 Intranasal administration Leukocytes (eosinophilic) Mice Monoclonal antibodies Original ORIGINAL ARTICLES Phenotypes Polyposis Respiratory function Sinusitis type 2 inflammation IL-4 cytokines IL-13 type 2 inflammation dupilumab
ISSN:	0105-4538, 1398-9995, 1398-9995
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!